I am sorry, but I have to disagree with your statement.
I have major issues with today's PR.
1) It is way too long, and way too technically detailed for my taste.
2) There are several repetitions in there, which does not make this sound very professional, in my view. As if nobody has proof read it, before it was sent out for publication.
3) The way it is written at the beginning, it sounds as if they have received a rejection from the FDA, and now need to respond. While in fact, they are now filing for their actual IND application, to request permission to go into clinical trials.
So, for me, the propper way of putting it would have been:
Headline
"IND application filed with the FDA to request permission for phase 1+ 2 clinical trials for our Complete Vaccine"
Body:
GNBT today announced that they have requested permission for phase 1+2 clinical trials from the FDA. In particular the company has updated the FDA in regards to their comments to company's Pre-IND application, including
1) ....
2) ... (as stated in the original PR)
Timelines are missing, and for sure it does not make anybody happy to read that the trial vaccine doses will be produced in May (basically in a month from now), and that the CEO is looking forward to starting the clinical trials "in summer". Yay, commencement of trials "in the comming months"!
"I am so excited, that I just can't hide it, I am about to loose control and I think I like it!" NOT!!
So, yes, in general it is good news to hear that they filed their IND application with the FDA, but isn't it rather funny to read about GNBT fast response to a pandemic, and in the next sentence they state that it took them 1 entire year to get to a point where they are now only a couple of months away from starting clinical trials, while at least 4 other competitors already have approved vaccines that have been adiministered to millions of people world wide?
Ok, ok, I get it, these are the big pharma companies that have addtionally received 100s of millions of dollars in BARDA funding, while GNBT did most of this on their own, but still I don't see any reason for them to brag about their fast response to a pandemic, or is my way of thinking totally out of line here?
And yes, I agree, another important information is missing, how all those updates provided to FDA today, gets the ball rolling again in China.
Sorry if this sounds overly negative or pessimistic, but it seems that the overall market response is similar to my thoughts on today's PR. I cannot say how much I would like to see the shareprice to skyrocket, but I can surely understand why it is not, based on this PR today.
I am honestly very much disappointed.
I have major issues with today's PR.
1) It is way too long, and way too technically detailed for my taste.
2) There are several repetitions in there, which does not make this sound very professional, in my view. As if nobody has proof read it, before it was sent out for publication.
3) The way it is written at the beginning, it sounds as if they have received a rejection from the FDA, and now need to respond. While in fact, they are now filing for their actual IND application, to request permission to go into clinical trials.
So, for me, the propper way of putting it would have been:
Headline
"IND application filed with the FDA to request permission for phase 1+ 2 clinical trials for our Complete Vaccine"
Body:
GNBT today announced that they have requested permission for phase 1+2 clinical trials from the FDA. In particular the company has updated the FDA in regards to their comments to company's Pre-IND application, including
1) ....
2) ... (as stated in the original PR)
Timelines are missing, and for sure it does not make anybody happy to read that the trial vaccine doses will be produced in May (basically in a month from now), and that the CEO is looking forward to starting the clinical trials "in summer". Yay, commencement of trials "in the comming months"!
"I am so excited, that I just can't hide it, I am about to loose control and I think I like it!" NOT!!
So, yes, in general it is good news to hear that they filed their IND application with the FDA, but isn't it rather funny to read about GNBT fast response to a pandemic, and in the next sentence they state that it took them 1 entire year to get to a point where they are now only a couple of months away from starting clinical trials, while at least 4 other competitors already have approved vaccines that have been adiministered to millions of people world wide?
Ok, ok, I get it, these are the big pharma companies that have addtionally received 100s of millions of dollars in BARDA funding, while GNBT did most of this on their own, but still I don't see any reason for them to brag about their fast response to a pandemic, or is my way of thinking totally out of line here?
And yes, I agree, another important information is missing, how all those updates provided to FDA today, gets the ball rolling again in China.
Sorry if this sounds overly negative or pessimistic, but it seems that the overall market response is similar to my thoughts on today's PR. I cannot say how much I would like to see the shareprice to skyrocket, but I can surely understand why it is not, based on this PR today.
I am honestly very much disappointed.
6
